学习与工作经历：

1992.09-1997.06，济宁医学院临床医学专业，学士

1997.10-2005.07，济宁市精神病防治院，医师，2003年晋主治医师

2005.09-2010.06，中南大学湘雅医学院，攻读硕士和博士学位

2010.08-2020.03，山东省精神卫生中心，副主任医师

2020.03----至今，山东省精神卫生中心，主任医师

 

研究方向：

临床精神药理学，生物精神病学

 

学术/社会兼职：

中华医学会精神医学分会生物精神病学组委员

中国医师协会精神科医学分会抑郁障碍学组委员

 

获奖荣誉：

本科生课程：

精神病学、全科医学

研究生课程：

精神病学

1.精神分裂症的遗传易感性-ITIH2基因多态性与阿立哌唑改善抗精神病药物所致高泌乳素血症效果的关联研究. 合作课题. 2023.11-2024.11.  5万元. 分中心PI

2.SYHF2036-001. 棕榈酸帕利哌酮注射液在中国精神分裂症患者中的随机、开放、多中心、两制剂、多次给药、平行设计生物等效性试验项目. 横向课题. 2023.12-2025.02. 108.7万. 分中心PI

3.202303090712. 单/双相抑郁障碍认知任务下的额叶α波不对称和功能性近红外光谱研究. 山东省医药卫生科技项目,  2024.01-2025.12,  8万元, PI

4.盐酸托鲁地文拉法辛缓释片治疗难治性抑郁症的疗效与安全性. 横向课题, 2024.02- 2024.10, 26.7万,  PI

5.棕榈酸帕利哌酮注射液（3M）在中国精神分裂症患者中的随机、开放、多中心、两制剂、多次给药、平行设计生物等效性试验. 横向课题, 2025.02-2026.12, 63.3万元, 分中心PI

6.文拉法辛缓释胶囊与琥珀酸地文拉法辛缓释片治疗SSRI疗效不佳的抑郁症患者的疗效和安全性的平行对照研究. 横向课题. 2025.11-2026.11, 11万, PI

发表论文(第一或并列第一作者/通讯作者)：

1.Efficacy and safety of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study. Psychopharmacology, 2011, 213(2-3): 639-646.

2.No significant association between RELN polymorphism and autism in case-control and family-based association study in Chinese Han population. Psychiatry Research, 2011, 187(3):462-464.

3.Mutation analysis of the NRXN1 gene in a Chinese autism cohort. Journal of Psychiatric Research, 2012, 46(5):630-634.

4.Disruption of contactin 4 in two subjects with autism in Chinese population. Gene, 2012, 505(2):201-205.

5.Early and late onset, first-episode, treatment-naive depression: same clinical symptoms, different regional neural activities. Journal of Affective Disorders, 2012, 143(1-3):56-63.

6.Reversal alterations of amplitude of low-frequency fluctuations in early and late onset first-episode, drug-naive depression. Progress in Neuro-psychopharmacology & biological Psychiatry, 2013, 40:153-159.

7.Disrupted white matter integrity in first-episode, drug-naive, late-onset depression. Journal of affective disorders, 2014, 163: 70-75.

8.Association and gene-gene interactions study of reelin signaling pathway related genes with autism in the Han Chinese population. AutismResearch,2016,9(4):436-442.

9.Peripheral non-enzymatic antioxidants in patients with schizophrenia: a case-control study. BMC Psychiatry,2020,20(1):241

10.Pathological gambling in a patient on piribedil: a case report. Medicine, 2021,100:6(e24568)

11.Neurocognitionfunction ofpatientswithbipolardepression,unipolardepression, anddepressionwithbipolarity. Frontiers in Psychiatry, 2021,12:696903.

12.Individuals with bipolar disorderhave a higher level of uric acidthan major depressive disorder:a case-control study. Scientific reports, 2021, 11(1):18307.

13.Peripheral non-enzymatic antioxidants as biomarkers for mood disorders: evidence from a machine learning prediction model. Frontiers in Psychiatry, 2022,13:1019618.

14.Individuals with bipolar disorder have a higher level of homocysteine than major depressive disorder: a retrospective chart review and observational study. Neuropsychiatric Disease and Treatment, 2022,18:2671-2682.

15.Effect of aripiprazole on promoting cognitive function and enhancing clinical efficacy in patients with firs-episode depression on escitalopram: a randomized controlled trial. Journal of Affective Disorders, 2024, 344:159-168.

16.Cohen syndrome combined with psychiatric symptoms: a case report. BMC Psychiatry, 2024, 24:180..

17.Efficacy and Safety of Ziprasidone Injection vs Haloperidol Injection for Agitation in Patients with Acute Schizophrenia.Alpha Psychiatry. 2025,26(2):40032.

18.Efficacy and safety of Toludesvenlafaxine extended-release tablets in the treatment of treatment-resistant depression. BMC Psychiatry, 2025.

19.Frontal alpha asymmetry across genders as a distinction between major depressive disorder and bipolar disorder. Journal of Affective Disorders, 2026, 395(Pt B):120777.

20.首发未用药老年抑郁症患者脑MRI异常信号分析.精神医学杂志, 2011, 24(5):321-324.

21.首次发病未用药老年抑郁症患者脑白质完整性的弥散张量成像研究.中华精神科杂志, 2010, 43(2): 75-78.

22.艾司西酞普兰与西酞普兰治疗抑郁症的随机、双盲、双模拟、多中心平行对照研究.中国新药与临床杂志,2009,28(4):263-267.

23.精神科物理治疗方法的进展.国际精神病学杂志, 2009, 36(1):61-64.

24.抑郁症的功能磁共振研究进展.医学临床研究,2006,23(10):1650-1654.

25.汉族儿童孤独症核心家系血浆谷氨酸和γ-氨基丁酸水平的对照研究.新乡医学院学报,2010,27(2):150-153.

26.奥氮平所致不宁腿综合征二例报告.精神医学杂志, 2012, 25(3): 214.

27.利培酮、喹硫平、齐拉西酮对首发精神分裂症患者代谢指标的影响.临床心身疾病杂志,2016,22(4):10-13.

28.抑郁症患者血清hs-CRP水平变化及其对抗抑郁药疗效的预测作用.山东大学学报医学版, 2018, 56(6):51-57.

29.嘌呤能系统在精神疾病中的研究进展.精神医学杂志,2018,31(6):471-475.

30.抗精神病药物治疗对精神分裂症患者外周血非酶类抗氧化物水平的影响.精神医学杂志,2019,32(4):260-264.

31.拉莫三嗪在精神科临床应用的研究进展.精神医学杂志,2019,32(6):475-480.

32.利培酮合并小剂量阿立哌唑对女性精神分裂症患者疗效对照研究.系统医学,2020,5(4):13-15.

33.中药方剂改善精神科药物所致不良反应研究进展.社区医学杂志,2023,21(20):1085-1091.

34.肠道菌群在青少年抑郁障碍发病机制中的研究.系统医学,2024,9(15):191-194.

35.精神科药物对尿酸水平影响的研究进展.国际精神病学杂志,2024,51(2):345-348.

36.青少年抑郁障碍患者伴非自杀性自伤行为的研究进展.国际精神病学杂志,2024,51(6):1684-1687.

37.神经电生理及功能性近红外光谱在心境障碍诊断中的研究进展.医药前沿, 2024,14(25):21-23,27.

舒肝解郁胶囊联合艾司西酞普兰或度洛西汀治疗老年期抑郁障碍的对照研究.精神医学杂志,2024,37(4): 414-420.